Current challenges and unresolved problems in hypertensive disease.
Over the past four or five decades, hypertension and cardiovascular medicine has experienced dramatic and innovative changes that have significantly reduced morbidity and mortality. A vast array of new antihypertensive compounds have been developed, which are able to inhibit many pathophysiologic mechanisms of the disease and prevent many of the outcomes in patients with hypertension. Much of this series of therapeutic breakthroughs have been the result of active participation of clinical scientists with tremendous and remarkable knowledge of and experience with the fundamental mechanisms of disease. In more recent years, much new information has appeared concerning the basis genetic and biologic mechanisms involved in cardiovascular and renal diseases. What remains of utmost importance is for members of the academic community with a wide spectrum of experience and points of view to continue to work with the fundamental problems and mechanisms of the diseases.
Ochsner Clinic Foundation, New Orleans, LA 70121, USA. efrohlich@ochsner.org
Edward D
ED
Frohlich
D000959:Antihypertensive Agents / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D008019:Life Style; D009765:Obesity / Q000150:complications; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D012982:Sodium, Dietary / Q000009:adverse effects
D000959:Antihypertensive Agents; D012982:Sodium, Dietary